18 results about "Novel virus" patented technology

The disclosure provides novel virus packaging elements and cells transduced by such elements to enable large-scale library screens with combinatorial elements that heretofore were impractical due to the presence of recombination between library elements that occurs during conventional lentivirus production and transduction of target cells. The present disclosure overcomes these problems by generating clonal virus packaging cells that each produce a genetically homologous virus.

The application provides a DNA virus tracer coated with a protein by an EDC covalent coupling method and a preparation method and application thereof. The DNA virus tracer coated with the protein of the application is composed of a core, a shell and a protein shell coated on the shell; the core is a SiO2 nanosphere with adsorbed nucleic acid on the surface, a layer of SiO2 shell is coated on the outside of the core, the surface of the shell is modified by carboxylation, and the shell is formed by covalently coupling the protein through EDC. The novel DNA virus tracer provided by the application can effectively protect the coding DNA, facilitate subsequent quantitative detection and analysis, effectively ensure that the outermost shell of the tracer is completely composed of the selected protein, and make the surface characteristics and migration characteristics of the tracer closer to the target virus.

A novel virus detection reagent bottle facilitating detection operation comprises a reagent bottle body, a bottle cap connected with the reagent bottle body through threads is arranged at the upper end of the reagent bottle body, a concave connecting counter bore is formed in the upper end of the bottle cap, a sealing film is arranged at the bottom of the connecting counter bore, and the connecting counter bore is detachably connected with a suction capsule body through threads. A through hole is formed in the suction capsule body and communicated with the capsule on the upper portion of the suction capsule body, a capsule sealing film is arranged at the bottom of the through hole of the suction capsule body, and an inner cavity of the bottle cap is detachably connected with the liquid taking pipe device through threads. The liquid taking pipe device extrudes and tears the sealing film and the capsule sealing film so that the sucked capsule body can be communicated with the liquid taking pipe device. A cut-off type through operation is replaced by an extrusion tearing type, fragments cannot be generated to pollute sampling, suction is smoother, blockage is not prone to occurring, a sealing film can be additionally arranged at the bottom of the capsule body, the interior of the capsule body is prevented from being polluted, and the film body is torn through the conical boss in the using process.

The present application relates to viral sensitizers. More specifically, the present application relates to compounds of Formula (I), as well as methods of using such compounds as viral sensitizers, specifically for increasing permissiveness of a cell to the production of virus from reverse genetics systems, replicating viruses, and increasing transduction. Formula (I).

The present application relates to viral sensitizers. More specifically, the present application relates to compounds, as well as methods of using such compounds as viral sensitizers, specifically for increasing permissiveness of a cell to the production of virus from reverse genetics systems, replicating viruses, and increasing transduction.

The present invention offers a new approach for highly multiplexed, programmable antiviral therapies that directly target viral RNA, and can be flexibly adapted to target novel viruses or emerging outbreak pathogens. Class 2, type VI CRISPR system-based therapies can be used in combination with existing antiviral compounds for viruses where such compounds exist, either by increasing their efficacy or by preventing the evolution of specific drug resistance mutations. Perhaps most excitingly, if a virus evolves resistance to a specific guide RNA sequence, it is easy to switch to a different guide RNA sequence, or to design a new guide sequence to target the new mutation. Such approaches should prevent the widespread development of resistance to Class 2, type VI CRISPR system-based therapies.

A gene therapy drug for treating X-linked retinoschisis. The drug comprises a gene expression cassette expressing the retinoschisis protein (RS1 protein), enabling high-level expression of RS1 protein. By constructing a novel AAV viral vector, the RS1 protein is delivered into target cells. This effectively compensates for X-linked retinoschisis and related eye diseases caused by RS1 gene mutations, fundamentally treating X-linked retinoschisis and its complications, and improving vision.

The present invention provides novel capsid variants for viral vectors that detarget liver tissue.

rAAV particles comprising a new capsid variant, AAV44.9(E531D) are described herein, as well as a polynucleotide encoding same, and the use of the rAAV particles in the treatment of the eye, including treatment of retinal disorders. The disclosure also shows that the rAAV particles comprising an AAV44.9(E531D) capsid exhibit enhanced lateral spread after subretinal injection to a fovea of the subject, wherein detachment of the fovea is minimized. Methods of treatment comprising administering rAAV particles to a mammal in need thereof, and methods of transducing photoreceptor and RPE cells with rAAV particles, are also provided.

This application provides novel viral envelope glycoproteins for pseudotyping viral vectors, novel designs of synthetic antigen receptors (SARs), novel signaling chains for constructing SARs, novel antigen-binding domains, and novel methods for producing SAR-expressing cells. These novel methods and compositions are widely used in cell therapy.

The invention relates to the field of virus sampling, and discloses a novel virus sampling tube and a sampling method thereof.The novel virus sampling tube comprises a tube body, sample liquid is arranged in the tube body, threads are formed in the outer side of a port of the tube body, a tube cover is arranged at the top of the tube body, a sealing plug is arranged at the bottom of the tube cover, and the sealing plug is in sealing fit with the port of the tube body; a spiral groove is formed in the pipe cover, the spiral groove is matched with the thread at the end opening of the pipe body, and a power assisting assembly is further arranged on the pipe cover and used for assisting the opening action of the pipe cover. Through the upward prying effect of the extending end part of the lever on the sealing plug, the joint of the power-assisted cover body and the pipe cover part is broken and separated, so that the power-assisted cover body drives the sealing plug and the pipe body to be separated from an initial tight sealing state, and at the moment, the power-assisted cover body only needs to be slightly pulled out with the other hand; and the situation that two hands are strenuous to screw can be effectively relieved through the lever effect.

The present invention relates to a novel genotype of severe fever with thrombocytopenia syndrome viruses and use thereof as an immunogenic composition. The severe fever with thrombocytopenia syndrome viruses of the present invention are genetically different from conventional severe fever with thrombocytopenia syndrome viruses and are novel viruses taxonomically belonging to three sub-groups of genotype B. In view of the vaccine property that specific genotype viruses alone show only limited protective potential, the novel viruses of the present invention may be advantageously used as a vaccine having excellent cross-immunogenicity for SFTSV.

The present application provides novel viral envelope glycoproteins for viral vector pseudotyping, novel designs for synthetic antigen receptors (SARs), novel signal chains for constructing SAR, novel antigen binding domains, and novel methods for generating SAR expressing cells. These novel methods and compositions have broad applications in cell therapy.

Described herein are novel compositions comprising a virus or viral vector that may express viral glycoproteins, and methods of treatment using the same.

This invention provides an in vitro packaging method for ring virus pseudovirus particles, belonging to the field of molecular biology technology. The method involves eukaryotic expression of a ring virus capsid expression plasmid. Ring virus pseudovirus particles can serve as a safe and efficient novel viral vector for gene therapy and basic research. The technical method of this invention will promote basic research on ring viruses and related vector-based applications.

To provide a new method for detecting a virus by which many kinds of viruses derived from various species can efficiently and accurately be detected in one reaction to improve diagnostic efficiency and provide a reliable detection result.SOLUTION: The present invention provides a virus detection method comprising the steps of: immobilizing virus nucleic acid primer sequences corresponding to viruses derived from various species on a solid-phase support; supplying a specimen sample to the solid-phase support; setting a plurality of amplification reaction conditions; and performing an amplification reaction on the specimen sample supplied to the solid-phase support based on the amplification reaction conditions to simultaneously detect a plurality of viruses derived from various species under the amplification reaction.SELECTED DRAWING: Figure 1

The present invention deals with a novel virus-like particle (VLP) platform for developing enhanced vaccines. This novel VLP-platform consists of two unique attributes: i) intein-mediated protein bioconjugation, a method that allows for precise and efficient attachment of target antigens to the VLP surface without leaving undesirable residual tags or scars; and ii) encapsulation of different small molecule immunomodulators (including cytokines, adjuvants, and small molecule metabolites) for specific priming of tailored immune response through influencing the outcome of interactions between the antigen-presenting cells (APCs) and the T-cells towards eliciting a specific type of immune response (Th1: humoral, Th1: cell mediated, Tfh, Th2, Th17, or Treg). This intein-mediated bioconjugation based VLP platform facilitates a "plug-and-display" approach, significantly reducing the time and resources required for development of vaccines suitable for a wide range of applications, including vaccines against infectious diseases, cancer immunotherapies, and treatments for autoimmune disorders. Additionally, encapsulation of immunomodulatory factors within the VLP core, enables delivery to APCs thereby generating robust and specific type of immune response for enhanced vaccine efficacy. This invention provides a versatile, scalable, and cost-effective solution for rapid development of vaccines that induce comprehensive and tailored immune responses, including both humoral and cellular immunity with long-term memory.

A novel virus detection reagent bottle facilitating detection operation comprises a reagent bottle body, a bottle cap connected with the reagent bottle body through threads is arranged at the upper end of the reagent bottle body, a concave connecting counter bore is formed in the upper end of the bottle cap, a sealing film is arranged at the bottom of the connecting counter bore, and the connecting counter bore is detachably connected with a suction capsule body through threads. A through hole is formed in the suction capsule body and communicated with the capsule on the upper portion of the suction capsule body, a capsule sealing film is arranged at the bottom of the through hole of the suction capsule body, and an inner cavity of the bottle cap is detachably connected with the liquid taking pipe device through threads. And a device for quantitatively taking liquid from the reagent bottle is arranged on the suction capsule body. The capsule is extruded in a quantitative volume through the variable-diameter structure, liquid sucked when the capsule is deformed and recovered can be quantitatively controlled, a reagent can be conveniently and quantitatively taken, and the reagent can be conveniently inspected and used.